Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.63 |
| ▸ | PDE4A | P27815 | 9/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833835 | 1.00 | PDE4B (0.63) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL3610006 | 0.85 | MAPT (0.65) | PDE4BPDE4DPDE4APDE4CLMNA | |
| SCHEMBL3609373 | 0.85 | MAPT (0.65) | PDE4BPDE4DPDE4APDE4CLMNA | |
| SCHEMBL3603468 | 0.81 | MAPT (0.77) | LMNAMAPT | |
| SCHEMBL3603472 | 0.81 | MAPT (0.77) | LMNAMAPT | |
| SCHEMBL132715 | 0.81 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL1030007 | 0.80 | PDE4B (0.72) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL29723288 | 0.80 | PDE4B (0.72) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL6461060 | 0.79 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL29723540 | 0.79 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143262-B2 | 7-(3′,4′-Dialkoxyphenyl)[1,2,4]-triazolo[1,5-A]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| US-20100105704-A1 | 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-04-29 | — | — | US | disclosed |
| WO-2008117943-A1 | 7-(3',4'-DIALKOXYPHENYL)-[1,2,4]-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS, PROCESS FOR PREPARING THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ARTHRITIS, ATOPIC DERMATITIS, TUMOR AND DEGENERATIVE BRAIN DISEASES COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105704-A1 | 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same | TSLP, IL5, ADORA1 | PDE4B 550/4885PDE4D 585/4885PDE4A 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.